| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 4, Human | 20 | 2022 | 178 | 2.530 |
Why?
|
| Receptors, Complement 3d | 11 | 2016 | 16 | 1.650 |
Why?
|
| B-Lymphocytes | 9 | 2015 | 550 | 1.040 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2022 | 89 | 1.020 |
Why?
|
| Thymidine Kinase | 7 | 2010 | 18 | 0.990 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 38 | 0.890 |
Why?
|
| Viral Matrix Proteins | 5 | 2016 | 47 | 0.790 |
Why?
|
| Herpesvirus 8, Human | 6 | 2005 | 16 | 0.630 |
Why?
|
| Fetal Proteins | 2 | 2012 | 8 | 0.620 |
Why?
|
| Ganciclovir | 6 | 2018 | 18 | 0.550 |
Why?
|
| Virus Attachment | 2 | 2014 | 18 | 0.550 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 689 | 0.530 |
Why?
|
| Antiviral Agents | 6 | 2013 | 313 | 0.480 |
Why?
|
| Sarcoma, Kaposi | 3 | 2005 | 15 | 0.460 |
Why?
|
| Virion | 1 | 2015 | 119 | 0.450 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 750 | 0.440 |
Why?
|
| Receptors, Complement 3b | 2 | 2013 | 12 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 178 | 0.420 |
Why?
|
| Herpesviridae Infections | 3 | 2002 | 25 | 0.400 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 137 | 0.380 |
Why?
|
| Receptors, Immunologic | 3 | 2012 | 176 | 0.380 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 240 | 0.380 |
Why?
|
| Receptors, Complement | 5 | 1990 | 17 | 0.380 |
Why?
|
| Spleen | 1 | 2012 | 479 | 0.350 |
Why?
|
| Cell Differentiation | 2 | 2016 | 1304 | 0.320 |
Why?
|
| Cell Line | 10 | 2015 | 1983 | 0.310 |
Why?
|
| Acyclovir | 3 | 2010 | 19 | 0.280 |
Why?
|
| Centrioles | 1 | 2007 | 26 | 0.270 |
Why?
|
| Rhadinovirus | 1 | 2005 | 4 | 0.260 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 169 | 0.240 |
Why?
|
| Humans | 37 | 2022 | 59389 | 0.230 |
Why?
|
| Protein Binding | 5 | 2015 | 1555 | 0.230 |
Why?
|
| Phosphoproteins | 1 | 2005 | 211 | 0.230 |
Why?
|
| Open Reading Frames | 4 | 2005 | 80 | 0.230 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 656 | 0.220 |
Why?
|
| Zidovudine | 2 | 2018 | 12 | 0.210 |
Why?
|
| Virus Replication | 5 | 2013 | 305 | 0.210 |
Why?
|
| Bone Marrow Transplantation | 3 | 1998 | 138 | 0.210 |
Why?
|
| Complement C3d | 1 | 2002 | 2 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2015 | 343 | 0.200 |
Why?
|
| Infectious Mononucleosis | 1 | 2022 | 33 | 0.190 |
Why?
|
| Serogroup | 1 | 2021 | 32 | 0.190 |
Why?
|
| Molecular Sequence Data | 9 | 2007 | 1951 | 0.190 |
Why?
|
| Herpesvirus 1, Human | 2 | 2000 | 78 | 0.190 |
Why?
|
| Cell Adhesion | 2 | 2015 | 206 | 0.180 |
Why?
|
| DNA, Viral | 6 | 2016 | 223 | 0.170 |
Why?
|
| Herpesviridae | 1 | 2000 | 14 | 0.170 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2000 | 5 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 100 | 0.160 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1998 | 46 | 0.160 |
Why?
|
| Receptors, Virus | 3 | 1990 | 67 | 0.150 |
Why?
|
| Hepatitis B virus | 1 | 1998 | 13 | 0.150 |
Why?
|
| Hepatitis B | 1 | 1998 | 28 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1998 | 32 | 0.150 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 847 | 0.140 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 56 | 0.140 |
Why?
|
| Bacteriophages | 1 | 1998 | 49 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 68 | 0.140 |
Why?
|
| Herpes Zoster | 1 | 2017 | 23 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 74 | 0.130 |
Why?
|
| Cell Culture Techniques | 3 | 2016 | 178 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 193 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 292 | 0.130 |
Why?
|
| Liver | 1 | 2000 | 795 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 402 | 0.120 |
Why?
|
| Dependovirus | 1 | 2021 | 652 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 446 | 0.120 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1995 | 58 | 0.120 |
Why?
|
| Neutralization Tests | 1 | 2015 | 118 | 0.120 |
Why?
|
| Mucor | 1 | 1994 | 3 | 0.120 |
Why?
|
| Immunization | 1 | 2015 | 128 | 0.110 |
Why?
|
| Mucormycosis | 1 | 1994 | 10 | 0.110 |
Why?
|
| Amino Acid Sequence | 6 | 2007 | 1553 | 0.110 |
Why?
|
| Animals | 9 | 2016 | 19650 | 0.110 |
Why?
|
| Neutropenia | 1 | 1994 | 62 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 238 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2014 | 103 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 6 | 2002 | 450 | 0.110 |
Why?
|
| Benzoquinones | 1 | 2013 | 14 | 0.110 |
Why?
|
| Lactams, Macrocyclic | 1 | 2013 | 25 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 1995 | 254 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1118 | 0.110 |
Why?
|
| Butyrates | 2 | 2006 | 15 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 8 | 0.100 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 19 | 0.100 |
Why?
|
| K562 Cells | 1 | 2013 | 57 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 868 | 0.100 |
Why?
|
| Transfection | 2 | 2013 | 675 | 0.100 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1990 | 24 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 297 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 64 | 0.100 |
Why?
|
| Duffy Blood-Group System | 1 | 2012 | 1 | 0.100 |
Why?
|
| Arginine | 2 | 2006 | 110 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2013 | 142 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 1998 | 808 | 0.100 |
Why?
|
| Cell Line, Transformed | 3 | 2004 | 98 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 718 | 0.100 |
Why?
|
| Virus Internalization | 1 | 2013 | 81 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1994 | 167 | 0.100 |
Why?
|
| Receptors, IgE | 1 | 2011 | 6 | 0.090 |
Why?
|
| Temperature | 1 | 2013 | 295 | 0.090 |
Why?
|
| Gene Expression | 2 | 2014 | 809 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 986 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 347 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 86 | 0.090 |
Why?
|
| Epithelial Cells | 3 | 2016 | 391 | 0.090 |
Why?
|
| Virus Latency | 2 | 2002 | 29 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 490 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2010 | 883 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 789 | 0.080 |
Why?
|
| Viral Proteins | 2 | 2010 | 253 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 428 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2016 | 2900 | 0.080 |
Why?
|
| Virus Cultivation | 2 | 2013 | 18 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 1151 | 0.080 |
Why?
|
| Cricetinae | 2 | 2007 | 366 | 0.080 |
Why?
|
| Substrate Specificity | 2 | 2000 | 333 | 0.070 |
Why?
|
| Genes, Viral | 1 | 1988 | 55 | 0.070 |
Why?
|
| Mutation | 3 | 2013 | 2456 | 0.070 |
Why?
|
| Female | 10 | 2022 | 30726 | 0.070 |
Why?
|
| Base Sequence | 4 | 1998 | 1302 | 0.070 |
Why?
|
| Cricetulus | 1 | 2007 | 99 | 0.070 |
Why?
|
| Adult | 9 | 2022 | 15681 | 0.070 |
Why?
|
| CHO Cells | 1 | 2007 | 189 | 0.070 |
Why?
|
| Tubulin | 1 | 2007 | 72 | 0.070 |
Why?
|
| Centrosome | 1 | 2007 | 71 | 0.070 |
Why?
|
| Biomarkers | 1 | 2012 | 1307 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 356 | 0.070 |
Why?
|
| Cell Transformation, Viral | 2 | 2004 | 15 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 2016 | 2092 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 628 | 0.070 |
Why?
|
| Neoplasms | 1 | 2016 | 1231 | 0.060 |
Why?
|
| Lymphoma | 1 | 2006 | 99 | 0.060 |
Why?
|
| Mice | 6 | 2016 | 10291 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2005 | 21 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1552 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 1999 | 836 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 382 | 0.060 |
Why?
|
| Endothelium | 1 | 2004 | 18 | 0.060 |
Why?
|
| Male | 8 | 2018 | 27749 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 34 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 65 | 0.060 |
Why?
|
| 3T3 Cells | 1 | 2004 | 108 | 0.060 |
Why?
|
| Child | 3 | 2022 | 4189 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2004 | 31 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2011 | 1128 | 0.050 |
Why?
|
| Hepatitis C | 2 | 1996 | 143 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2004 | 117 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2002 | 259 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 270 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2004 | 526 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 354 | 0.050 |
Why?
|
| Carbohydrate Sequence | 1 | 2002 | 22 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 392 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 99 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2005 | 318 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 247 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2005 | 645 | 0.050 |
Why?
|
| Multiple Myeloma | 2 | 1999 | 325 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 424 | 0.050 |
Why?
|
| RNA, Messenger | 3 | 1999 | 1466 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 1991 | 381 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 1998 | 244 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2002 | 271 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 10 | 0.040 |
Why?
|
| Deoxyribonucleosides | 1 | 2000 | 3 | 0.040 |
Why?
|
| Diphosphates | 1 | 2000 | 10 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 1368 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2000 | 60 | 0.040 |
Why?
|
| Tritium | 1 | 2000 | 22 | 0.040 |
Why?
|
| Lung Transplantation | 2 | 1998 | 67 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 9 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2000 | 1284 | 0.040 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1999 | 8 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 4986 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1143 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 47 | 0.040 |
Why?
|
| Tissue Donors | 2 | 1996 | 143 | 0.040 |
Why?
|
| Stromal Cells | 1 | 1999 | 65 | 0.040 |
Why?
|
| Prokaryotic Cells | 1 | 1998 | 7 | 0.040 |
Why?
|
| Time Factors | 2 | 2005 | 3617 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 1234 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 1998 | 35 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 1999 | 112 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 1999 | 234 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1998 | 46 | 0.040 |
Why?
|
| Young Adult | 2 | 2022 | 4272 | 0.040 |
Why?
|
| Rituximab | 1 | 2018 | 80 | 0.040 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2017 | 6 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2018 | 53 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 1998 | 93 | 0.030 |
Why?
|
| DNA | 4 | 2005 | 805 | 0.030 |
Why?
|
| DNA Replication | 1 | 1999 | 228 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 396 | 0.030 |
Why?
|
| Apoptosis | 2 | 1999 | 1033 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2018 | 201 | 0.030 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 1996 | 1 | 0.030 |
Why?
|
| Blotting, Northern | 3 | 1992 | 148 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 410 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 446 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 188 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 62 | 0.030 |
Why?
|
| Binding Sites | 1 | 1998 | 881 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 214 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 67 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 228 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 223 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2005 | 495 | 0.030 |
Why?
|
| Adolescent | 2 | 2022 | 5838 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 191 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 245 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1998 | 474 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1995 | 6 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 8 | 0.030 |
Why?
|
| VDJ Recombinases | 1 | 1995 | 10 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1995 | 13 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 513 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1995 | 37 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 516 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2005 | 178 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 1996 | 551 | 0.030 |
Why?
|
| Dermatomycoses | 1 | 1994 | 13 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 21 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 29 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1995 | 57 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 289 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 801 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1597 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 1999 | 850 | 0.030 |
Why?
|
| HIV Infections | 1 | 2000 | 913 | 0.030 |
Why?
|
| Pregnancy | 1 | 2000 | 2213 | 0.030 |
Why?
|
| Middle Aged | 4 | 2018 | 16314 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 340 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 67 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 590 | 0.030 |
Why?
|
| Viral Load | 1 | 2013 | 220 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 584 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2338 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2002 | 841 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 33 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 105 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 377 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2011 | 83 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 111 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 177 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1992 | 309 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 225 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1991 | 192 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1507 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 472 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 238 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 51 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 858 | 0.020 |
Why?
|
| Multigene Family | 1 | 1990 | 92 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 88 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1991 | 244 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 51 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 248 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1989 | 27 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 400 | 0.020 |
Why?
|
| Proteins | 1 | 1995 | 730 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1989 | 114 | 0.020 |
Why?
|
| Cell Count | 1 | 1989 | 127 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1990 | 114 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1989 | 12 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 2000 | 116 | 0.020 |
Why?
|
| Cell Separation | 1 | 1989 | 145 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2005 | 583 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 179 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1989 | 258 | 0.020 |
Why?
|
| Stroke | 1 | 2017 | 1127 | 0.020 |
Why?
|
| Species Specificity | 1 | 1989 | 329 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1988 | 75 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 13408 | 0.020 |
Why?
|
| Cell Division | 1 | 1989 | 443 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1989 | 196 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5283 | 0.020 |
Why?
|
| Integrin alpha3beta1 | 1 | 2005 | 3 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2005 | 31 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 451 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 40 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 44 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2005 | 98 | 0.020 |
Why?
|
| Microcirculation | 1 | 2005 | 52 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 113 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 149 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2005 | 128 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1984 | 9 | 0.010 |
Why?
|
| Complement C3b | 1 | 1984 | 18 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 100 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 279 | 0.010 |
Why?
|
| Heparin | 1 | 2005 | 111 | 0.010 |
Why?
|
| Fluorescence | 1 | 1984 | 83 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 188 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 411 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 527 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 306 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 428 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2002 | 17 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 1793 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 1996 | 743 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 912 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 941 | 0.010 |
Why?
|
| Phenotype | 2 | 1996 | 1137 | 0.010 |
Why?
|
| Vero Cells | 1 | 2000 | 76 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 397 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 414 | 0.010 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 1999 | 11 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 650 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1999 | 19 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 43 | 0.010 |
Why?
|
| Cyclin D | 1 | 1999 | 4 | 0.010 |
Why?
|
| Cyclins | 1 | 1999 | 40 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 99 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1998 | 44 | 0.010 |
Why?
|
| Vincristine | 1 | 1998 | 25 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 75 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 132 | 0.010 |
Why?
|
| Prednisone | 1 | 1998 | 85 | 0.010 |
Why?
|
| Aspergillosis | 1 | 1998 | 40 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 97 | 0.010 |
Why?
|
| Necrosis | 1 | 1998 | 140 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 17 | 0.010 |
Why?
|
| Haplotypes | 1 | 1996 | 115 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1996 | 170 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1996 | 135 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 1994 | 6 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 289 | 0.010 |
Why?
|
| Hepacivirus | 1 | 1994 | 140 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 1992 | 15 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 52 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1991 | 60 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 1991 | 73 | 0.010 |
Why?
|
| Genes | 1 | 1991 | 90 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1998 | 1204 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1991 | 215 | 0.010 |
Why?
|